Nasdaq-listed Sonnet BioTherapeutics agrees to $888 million merger to become Hyperliquid Strategies, launch HYPE treasury

  • Hyperliquid Strategies is expected to hold 12.6 million HYPE tokens and $305 million in cash at closing of the deal.